NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $3.87 +0.12 (+3.20%) Closing price 04:00 PM EasternExtended Trading$3.83 -0.04 (-0.93%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IRWD alerts:Sign Up Key Stats Today's Range$3.67▼$3.9750-Day Range$3.63▼$4.5352-Week Range$1.41▼$5.78Volume2.40 million shsAverage Volume3.00 million shsMarket Capitalization$639.48 millionP/E Ratio5.03Dividend YieldN/APrice Target$6.23Consensus RatingModerate Buy Company Overview Ironwood Pharmaceuticals, Inc. is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs. Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners. Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions. The company’s pipeline has included additional therapies for gastrointestinal and related disorders, including programs obtained through its acquisition of VectivBio. Ironwood’s products and development programs serve patients in the United States and selected international markets through its commercial operations and collaboration network. Tom McCourt serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 541st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialIronwood Pharmaceuticals has a consensus price target of $6.23, representing about 61.1% upside from its current price of $3.87.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to decrease in the coming year, from $1.10 to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is 5.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is 5.03, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.17.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.50% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 13.11, which indicates bearish sentiment.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.42 News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows6 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.30% of the stock of Ironwood Pharmaceuticals is held by insiders.Percentage Held by InstitutionsIronwood Pharmaceuticals has minimal institutional ownership at this time.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRWD Stock News HeadlinesIronwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - BuyOctober 7 at 7:51 AM | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at Jefferies Financial GroupSeptember 28, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 8 at 1:00 AM | Porter & Company (Ad)Ironwood Pharmaceuticals, Inc. (IRWD)September 23, 2026 | finance.yahoo.comIronwood: Medicare Is Not The Problem I Thought It WasSeptember 11, 2026 | seekingalpha.comIronwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare ConferenceSeptember 3, 2026 | businesswire.comIronwood Pharmaceuticals: High Dependence On Its Next TrialAugust 26, 2026 | seekingalpha.comIronwood Pharmaceuticals Inc Class A IRWDAugust 13, 2026 | morningstar.comMSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $3.37 at the beginning of the year. Since then, IRWD stock has increased by 14.8% and is now trading at $3.87. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by $0.01. The biotechnology company had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 58.38% and a net margin of 33.36%. Read the conference call transcript. When did Ironwood Pharmaceuticals IPO? Ironwood Pharmaceuticals (IRWD) raised $250 million in an IPO on Wednesday, February 3rd 2010. The company issued 16,666,667 shares at a price of $14.00-$16.00 per share. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/06/2026Today10/08/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IRWD's financial health is in the Green zone, according to TradeSmith. IRWD has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees100Year Founded1998Price Target and Rating Average Price Target for Ironwood Pharmaceuticals$6.23 High Price Target$10.00 Low Price Target$3.70 Potential Upside/Downside+61.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.77 Trailing P/E Ratio5.03 Forward P/E Ratio3.52 P/E GrowthN/ANet Income$24.02 million Net Margins33.36% Pretax Margin53.27% Return on Equity-58.38% Return on Assets34.93% Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06 Sales & Book Value Annual Sales$296.15 million Price / Sales2.16 Cash Flow$0.27 per share Price / Cash Flow14.10 Book Value($1.61) per share Price / Book-2.40Miscellaneous Outstanding Shares165,240,000Free Float149,873,000Market Cap$639.48 million OptionableOptionable Beta0.21 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IRWD) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
